Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

FED × Rituximab × Other hematologic neoplasm × Clear all

Phase

Status

Sponsor Class

OTHER 240 INDUSTRY 79 NIH 39 NETWORK 8 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Clofarabine 2 talabostat 1 Topotecan 1 Tablets 1 Rituximab 1 PT-100 dipeptide 1 Mitoxantrone 1 Midazolam 1 Ketamine 1 Exercise 1 Etoposide 1 Dosage Forms 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00086203 2015-03-25

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

FDA Office of Orphan Products Development

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡